<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Crohn disease medications for pediatric patients, summary for patients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Crohn disease medications for pediatric patients, summary for patients</h1>
<div class="graphic"><div class="figure"><div class="ttl">Crohn disease medications for pediatric patients, summary for patients</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="centered highlight_gray_text" style="vertical-align: middle; border-bottom: black 3px solid;"><strong>Frequently asked questions</strong></td> <td class="centered highlight_gray_text" style="vertical-align: middle; border-bottom: black 3px solid;"><strong>Immunomodulator</strong><br/> Azathioprine (Imuran, Azasan); 6-MP (Purinethol), methotrexate</td> <td class="centered highlight_gray_text" style="vertical-align: middle; border-bottom: black 3px solid;"><strong>Anti-TNF</strong><br/> Infliximab (Remicade); adalimumab (Humira); certolizumab pegol (Cimzia)</td> <td class="centered highlight_gray_text" style="vertical-align: middle; border-bottom: black 3px solid;"><strong>Combination therapy</strong><br/> Immunomodulator plus anti-TNF</td> </tr> <tr class="divider_bottom"> <td><strong>What type of medication is this?</strong></td> <td>An immunomodulator is a medicine that is taken to regulate or quiet down the immune system, which then decreases inflammation.</td> <td>An anti-TNF drug blocks one specific chemical (TNF) in the body. Blocking TNF regulates or quiets down the immune system, which then decreases inflammation.</td> <td>Using an immunomodulator and an anti-TNF drug together.</td> </tr> <tr class="divider_bottom"> <td><strong>How is this treatment administered?</strong></td> <td>Daily, as a pill (azathioprine or 6-MP), or weekly, as a pill or shot (methotrexate). It may take weeks to months to be fully effective, so your doctor may prescribe a steroid, such as prednisone, to start.</td> <td>Infliximab is given intravenously (injected into the vein) 3 times in the first 6 weeks, then every 6 to 8 weeks. Adalimumab is given subcutaneously (injected under the skin) every other week, and certolizumab is given subcutaneously monthly. These medications act faster than immunomodulators, so you likely won't need steroids.</td> <td>Daily pill (or weekly shots if methotrexate) PLUS injections either intravenous (into the vein) or subcutaneous (under the skin).</td> </tr> <tr class="divider_bottom"> <td rowspan="2"><strong>After 6 months of treatment, how many people get relief of their symptoms and don't need steroids (eg, prednisone)?</strong></td> <td colspan="3">There are no research studies in children directly comparing immunomodulators to anti-TNF drugs to combination therapy. But, we do have good estimates based on research in children and adults for each of these options.</td> </tr> <tr class="divider_bottom"> <td>Approximately 40 people out of 100 (40%).</td> <td>Approximately 55 people out of 100 (55%).</td> <td>Approximately 60 people out of 100 (60%).</td> </tr> <tr class="divider_bottom"> <td><strong>What are some common, but short-lasting, side effects?</strong></td> <td>Approximately 3 people out of 100 (3%) develop pancreatitis, where the pancreas becomes inflamed and painful. Other short-term side-effects may include nausea, fever, fatigue, lowering of the white blood cell count, or increase in liver tests.</td> <td>Allergic reactions like a rash or shortness of breath from an infusion, or pain or swelling at the injection site can occur.</td> <td>With combination therapy, it's possible to get side effects from both immunomodulators and anti-TNF drugs.</td> </tr> <tr class="divider_bottom"> <td><strong>How common are serious infections?</strong></td> <td colspan="3">Approximately 3 to 6% (between 3 to 6 people out of 100) experience serious infections for each treatment option.</td> </tr> <tr class="divider_bottom"> <td><strong>How many people stop taking the medication because of side effects?</strong></td> <td>Approximately 10 out of 100 (10%).</td> <td>Approximately 6 to 7 people out of 100 (6 to 7%).</td> <td>If side effects occur, it might be possible to stop 1 of the medications and continue the other.</td> </tr> <tr class="divider_bottom"> <td><strong>What is the risk of getting lymphoma (lymph node cancer)?</strong></td> <td>Approximately 4 people out of 10,000 (0.04%) for azathioprine and 6-MP. It is not clear if methotrexate has any risk of lymphoma, but not enough research has been done to prove this.</td> <td>It is not clear that anti-TNF therapy on its own increases the risk of lymphoma at all, but not enough research has been done to prove this.</td> <td>There does not seem to be a meaningful increase in the risk of lymphoma if adding an anti-TNF to an immunomodulator. The risk is approximately 4 people out of 10,000 (0.04%).</td> </tr> <tr class="divider_bottom"> <td><strong>What else should I know about the risks of cancer?</strong></td> <td colspan="3">A rarer form of cancer is <strong>hepatosplenic T cell lymphoma</strong>. We don't know exactly how often it occurs, but it is very rare (less often than the type of lymphoma described above). It is seen mostly in young males. It is usually not treatable. This lymphoma has occurred in people taking 6-MP or azathioprine by itself, or as combination therapy with an anti-TNF drug. There have not been cases reported in Crohn disease with either methotrexate or anti-TNF therapy on its own.</td> </tr> <tr> <td><strong>What is the risk of getting lymphoma if not taking these medications?</strong></td> <td colspan="3">The risk of developing lymphoma in the general pediatric population is 0.0058%. This is equal to approximately 0.58 per 10,000 or 5 to 6 people out of 100,000.</td> </tr> </tbody></table></div><div class="graphic_lgnd">Option grid for the choice between immunomodulators, anti-TNF agents, and combination therapy for the treatment of pediatric Crohn disease. Option grids are intended to be reviewed with patients during an office visit to facilitate a shared decision-making process.</div><div class="graphic_footnotes">6-MP: 6-mercaptopurine; anti-TNF: anti-tumor necrosis factor; TNF: tumor necrosis factor.</div><div class="graphic_reference">From: Dulai PS, Siegel CA, Dubinsky MC. Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2013; 19:2927. DOI: <a href="http://journals.lww.com/ibdjournal/pages/articleviewer.aspx?year=2013&amp;issue=12000&amp;article=00024&amp;type=abstract" target="_blank">10.1097/MIB.0b013e31829aad16</a>. Copyright © 2013 Crohn's and Colitis Foundation of America, Inc. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 107130 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
